

# Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma

Information for the public

Published: 11 January 2023

[www.nice.org.uk](http://www.nice.org.uk)

Lenvatinib (Kisplyx) with pembrolizumab (Keytruda) is available on the NHS. It is a possible treatment for untreated advanced renal cell carcinoma in adults who have an intermediate or poor prognosis, if the alternative treatment would be nivolumab with ipilimumab.

If you are not eligible for lenvatinib with pembrolizumab but are already having it, you should be able to continue until you and your doctor decide when best to stop.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Kidney Cancer UK](#), 0800 002 9002
- [Action Kidney Cancer](#) (formerly Kidney Cancer Support Network) , 0800 121 8721
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4912-0